Immunotherapy resistance is associated with poor T cell infiltration into tumors. Tumor-cell-intrinsic oncogenic events that contribute to this defect include Wnt–β-catenin activation. PAK4 is now identified as an upstream modulator of this pathway, thus suggesting the potential of enhancing the efficacy of immunotherapy by targeting this druggable kinase.

中文翻译：

---

PAK4作为癌症免疫逃避靶点

免疫疗法抗性与 T 细胞浸润到肿瘤中较差有关。导致这种缺陷的肿瘤细胞内在致癌事件包括 Wnt-β-连环蛋白激活。PAK4 现在被确定为该途径的上游调节剂，因此表明通过靶向这种可药用激酶来增强免疫疗法功效的潜力。